News Wire

Drug-makers are racing to scoop up patient health records and strike deals with technology companies as big data analytics start to unlock a trove of information about how medicines perform in the real world, according to a Reuters report. Studying such real-world evidence (RWE) offers manufacturers…
Two new studies suggest that patients do better when providers switch from using intravenous saline therapy to balanced fluids that closely resemble the liquid part of blood. Vanderbilt University Medical Center researchers believe the studies could improve survival and decrease kidney complications.…
The FDA has approved a lidocaine topical system (ZTlido, Sorrento Therapeutics, Inc.), 1.8%, for the relief of pain associated with post-herpetic neuralgia (PHN) that Sorrento bills as “a major advancement in analgesics” because of improved adhesion. “ZTlido was designed to solve a problem that…
Nearly one in five health employees (18%) said they would be willing to sell confidential data to unauthorized parties, according to a new survey from consultant Accenture. The survey of 912 employees of provider and payer organizations in the United States and Canada found that the respondents willing…
Mylan N.V. and Revance Therapeutics, Inc., are teaming up to develop and market a biosimilar to Allergan’s Botox (onabotulinumtoxinA), the market-leading product in a neuromodulator market with overall sales estimated at $4 billion. The two companies announced a global collaboration and license agreement…
The National Comprehensive Cancer Network (NCCN) has released new NCCN Clinical Practice Guidelines in Oncology intended to help make sure people living with human immunodeficiency virus (HIV) infection who are diagnosed with cancer receive safe, necessary treatment. In 2010, an estimated 7,760 people…
Wilson’s disease patients had been champing at the bit for Teva Pharmaceuticals’ generic of Valeant Pharmaceuticals’ Syprine (trientine hydrochloride), which the company billed as a “lower-cost generic.” But after the drug launched this month, patients discovered Teva’s generic isn’t much…
The FDA has approved abemaciclib (Verzenio, Eli Lilly and Co.) in combination with an aromatase inhibitor (AI) as initial endocrine-based therapy for the treatment of postmenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–) advanced or metastatic…
Survival from cardiac arrest doubled when a bystander stepped in to apply an automated external defibrillator (AED) before emergency responders arrived, according to new research in the American Heart Association (AHA) journal Circulation. According to the AHA, of the more than 350,000 out-of-hospital…
Women face several options when it comes to birth control, so potential side effects often factor into their decision. Depression is a common concern for many women, but a new study by researchers at The Ohio State University (OSU) Wexner Medical Center is putting patients at ease. It found there’s…
Allergan’s attempt to protect six Restasis patents by assigning them to the St. Regis Mohawk Tribe has hit a snag: The U.S. Patent Trial and Appeal Board (PTAB) has denied the tribe’s motion to terminate Mylan's patent challenge. "The PTAB's ruling reinforces our belief that Allergan's maneuvers…
Commercially insured patients in health plans with value-based contracts for diabetes, high cholesterol, and human immunodeficiency virus medicines in the past two years had copays that averaged 28% lower for those medicines compared to patients in other plans, according to an analysis from the Pharmaceutical…
The FDA has approved a combination of acetaminophen and the prodrug benzhydrocodone (Apadaz, KemPharm, Inc.) that the manufacturer believes is “a differentiated product for the short-term management of acute pain.”  The FDA approved the immediate-release product for the short-term (no more than…
Dulaglutide (Trulicity, Eli Lilly and Company) significantly improved HbA1C when added to ongoing type-2 diabetes treatment with a sodium-glucose cotransporter-2 (SGLT-2) inhibitor, according to results from the phase 3b AWARD-10 trial. The data were published online in The Lancet Diabetes & Endocrinology…
Outpatient visits for flu-like illness dropped for a second week in a row but remained above the peak seen during many flu seasons, federal officials say. They predict that flu activity is likely to remain elevated for several weeks. During the week ending February 17—week 7 of this flu season—the…

Pages

Career Opportunities

HAP, a subsidiary of Henry Ford Health System, is a nonprofit health plan providing coverage to individuals, companies and organizations. This executive develops strategies to meet membership and revenue targets through products, pricing, market segmentation and advertising.  Aligns business among Business Development, Commercial Sales, Medicare and Public Sector Programs and Product Development. Seeks to enhance and be responsible for business development and expansion through the development of an effective product portfolio, strong interpersonal relationships and service excellence.

Apply via email to jfedder1@hfhs.org or online at http://p.rfer.us/HENRYFORDlXqAJA